BACR Events

THE CHALLENGES PREVENTING CANCER CURE

Why is it so hard to turn fundamental scientific knowledge into effective cures and how can we do this better in the future?   

A British Association for Cancer Research Conference in association with the Royal Society of Medicine.

10th – 12th March 2019, The Francis Crick Institute, London

Whilst there is general enthusiasm for recent developments in cancer medicine guided by analysis of an individual cancer patient's genomic alterations (“personalised medicine”) and for the use of immunotherapies for some cancers, there are major questions regarding the efficacy of novel therapies, their cost and whether they significantly impact on the survival of the majority of patients. This conference sets out to address these questions, with presentations both by advocates of current therapeutic approaches and those who consider that different or additional directions are necessary. It lays out the science which underlies the complexity and heterogeneity of advanced cancers and why they are so hard to eradicate. Presentations will also be made by clinician scientists, leading members of the pharmaceutical industry, healthcare analysts, and medicines agencies. Looking to the future and how early diagnosis may impact to increase survival and “cures”, experts in liquid biopsy, informatics, telemedicine and artificial intelligence will address emerging approaches. The program permits ample time for discussion including a concluding forum entitled “Cancer Medicine in 2030 and Beyond – How to Get Ready”. This meeting is unique in composition: its goal is to reflect realistically on the achievements of the cancer research community to date and their limitations, and to discuss ways forward to dramatically decrease mortality from cancer in the coming decades.

Speakers and Moderators

Julian Downward (Francis Crick, London, UK)

Vinay Prasad (Oregon Health and Science University, USA)

Charles Swanton (Francis Crick Institute, London, UK)

Serena Nik-Zainal (Sanger Centre, Cambridge, UK)

Christian Rommel (Roche, Basel, Switzerland)

Nils Lonberg (BMS, CA, USA)

Susan Galbraith (AZ, Cambridge, UK)

Johann De Bono (ICR, London, UK)

Paul Workman (ICR, London, UK)

William Hait (Johnson & Johnson, New Brunswick, USA)

Jack Scannell (UBS London & University of Edinburgh, UK)

John Reed (Sanofi-Aventis, Paris)

Ian Tannock (Univ Toronto, Canada)

Richard Sullivan (King’s College London, London, UK)

Tito Fojo (Columbia University, NYC, USA)

Sham Mailankody (MSKCC, NYC, USA)

Fred Steward (Policy Studies Institute, London, UK)

Jorge Camarero Jiménez (European Medicines Agency, Amsterdam, Netherlands)

Victoria Thomas (Head of Public Involvement, NICE, UK)

Ajay Aggarwal (Kings College London, London, UK)

John Hickman (Paris)

Ethan Basch (UNC Lineberger Comprehensive Cancer Center, NC, USA)

Alan Karthikesalingam (DeepMind, Google, London UK)

Lisa Hutchinson (London)

Klaus Pantel (UKE, Hamburg, Germany)

Nick Papadopoulos (Johns Hopkins University, Baltimore, USA)

Karen Vousden (Francis Crick Institute, London)

Requests for refunds must be made in writing no later than 10th February 2019.  No refunds will be made after this date; however substitution of delegates may be made at any time. 

Downloadable Documents

Suggested Hotels Close to The Francis Crick Institute.pdf
BACR Poster v2.pdf
Registration form for payments by cheque or bank transfer.doc
The Challenges Preventing Cancer Cure Programme.pdf

Prices

Regular Price
BACR/RSM Member 120.00
Non Member 150.00
BACR/RSM Students 80.00
Non Member Student 100.00

Tickets available: N/A

Start Date

05. 10. 2018

End Date

10. 03. 2019

Your information:

If you are paying on behalf of a delegate please enter their details below:

Choose your price:

Choose your options:

You will be given the option to opt in to having your email address published in the printed programme book which is handed out to participants and sponsors. If you do not opt in, we will not include your email address. We will also contact you about future conferences. All communications will contain the option to opt out.